ABVX

Abivax SA

Add to Watchlist

Advanced Chart

6.840

-0.090(-1.300%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

7.080

Open

7.040

VWAP

6.94

Vol

26.97K

Mkt Cap

433.54M

Low

6.760

Amount

187.13K

EV/EBITDA(TTM)

Total Shares

126.80M

711.51M

EV/OCF(TTM)

P/S(TTM)

Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

6 Analyst Rating

375.15% Upside

Wall Street analysts forecast ABVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABVX is 32.50 USD with a low forecast of 12.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

1 Hold

0 Sell

Strong Buy

375.15% Upside

Current: 6.840

Low

12.00

Averages

32.50

High

45.00

375.15% Upside

Current: 6.840

Low

12.00

Averages

32.50

High

45.00

Morgan Stanley

Judah Frommer

Hold

Initiates

$12

2025-03-20

Reason

Morgan Stanley

Judah Frommer

Price Target

$12

2025-03-20

Initiates

Hold

Reason

Morgan Stanley assumed coverage of Abivax with an Equal Weight rating and $12 price target. The Phase 2 results for obefazimod, Abivax's miR-124 upregulator, point to its potential as a safe, oral option for ulcerative colitis patients, the analyst tells investors in a research note. However, the firm believes the upcoming Phase 3 induction readout in Q3 "will be key in defining next steps for the company." The Equal Weight rating assumes the shares could remain range-bound until investors are presented with this data cut, contends Morgan Stanley.

Citizens Capital Markets

Jason Butler

Buy

Reiterates

$33

2025-03-18

Reason

Citizens Capital Markets

Jason Butler

Price Target

$33

2025-03-18

Reiterates

Buy

Reason

JMP Securities

Roy Buchanan

Buy

Reiterates

$33

2025-01-10

Reason

JMP Securities

Roy Buchanan

Price Target

$33

2025-01-10

Reiterates

Buy

Reason

JMP Securities

Jason Butler

Buy

Initiates

$33

2024-12-04

Reason

JMP Securities

Jason Butler

Price Target

$33

2024-12-04

Initiates

Buy

Reason

JMP Securities initiated coverage of Abivax with an Outperform rating and $33 price target. Abivax is focused on the development and commercialization of obefazimod, a novel immune modulator for the treatment of inflammatory bowel diseases, the analyst tells investors in a research note. The firm says the company has demonstrated "robust" Phase 2b results in patients with moderate-to-severe ulcerative colitis and results from two Phase 3 induction trials are anticipated in early Q2 of 2025. It believes the commercial potential for obefazimod is "compelling."

Laidlaw & Co.

Yale Jen

Strong Buy

Initiates

$48

2024-07-29

Reason

Laidlaw & Co.

Yale Jen

Price Target

$48

2024-07-29

Initiates

Strong Buy

Reason

BTIG

Julian Harrison

Strong Buy

Initiates

$43

2024-05-20

Reason

BTIG

Julian Harrison

Price Target

$43

2024-05-20

Initiates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Abivax SA (ABVX.O) is -2.14, compared to its 5-year average forward P/E of -8.58. For a more detailed relative valuation and DCF analysis to assess Abivax SA 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.58

Current PE

-2.14

Overvalued PE

5.05

Undervalued PE

-22.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-11.53

Current EV/EBITDA

-1.93

Overvalued EV/EBITDA

15.97

Undervalued EV/EBITDA

-39.04

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

243.05

Current PS

53.58

Overvalued PS

931.38

Undervalued PS

-445.27